



03-16-04

PATENT  
674519-2029

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Packham et al.  
U.S. Serial No. : 10/728,383  
Filing Date : December 5, 2003  
For : COMPOSITIONS COMPRISING OESTRONE-3-O-SULPHAMATE AND TRIAL (TNF-RELATED APOPTOSIS INDUCING LIGAND)  
Art Unit : To Be Assigned

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**

Mailing Label Number: EV 286858587 US

Date of Deposit: March 15, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Charles Jackson  
(Typed or printed name of person mailing paper or fee)

Charles Jackson  
(Signature of person mailing paper or fee)

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action, it is believed that no fee is required for entry of this paper. However, the


Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0320.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Applicants respectfully request that the Examiner considers and makes of record the documents cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants



Thomas J. Kowalski  
Reg. No. 32,147  
Deborah L. Lu  
Reg. No. 50,940  
(212) 588-0800

Encs. PTO Form 1449  
References (9)

Based on Form PTO-1449  
(3/90)

ATTY. DOCKET NO.

SERIAL NO.

674519-2029

10/728,383

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Packham et al.

FILING DATE

December 5, 2003

GROUP

To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AK	WO 00/66095	11/09/00	WIPO				
	AL	WO 99/64013	12/16/99	WIPO				
	AM	WO 97/01633	01/16/97	WIPO				
	AN							
	AO							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP		MacCarthy, L. et al., "Differential Effects of Estrone and Estrone-3-O-Sulfamate Derivatives on Mitotic Arrest, Apoptosis, and Microtubule Assembly in Human Breast Cancer Cells," <i>Cancer Research</i> , 60: 5441-50, 2000 (XP-001031282)
AQ		Pitti, R. et al., "Induction of Apoptosis by Apo-2-Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>Journal of Biological Chemistry</i> , 271(22): 12687-90, 1996 (XP-002031265)
AR		Purohit, A. et al., "The Development of A-ring Modified Analogues of Oestrone-3-O-sulphamate as Potent Steroid Sulphatase Inhibitors with Reduced Oestrogenicity," <i>J. Steroid Biochem. Molec. Biol.</i> , 64(5-6): 269-75, 1998 (XP-000852539)
AS		Purohit, A. et al., "The Effect of 2-Methoxyoestrone-3-O-Sulphamate on the Growth of Breast Cancer Cells and Induced Mammary Tumours," <i>Int. J. Cancer</i> , 85: 584-89, 2000 (XP-001039923)
AT		Spyridopoulos, I. et al., "Restoration of E2F Expression Rescues Vascular Endothelial Cells from Tumor Necrosis Factor- $\alpha$ -Induced Apoptosis," <i>Circulation</i> , 98:2883-90, 1998 (XP-002214772)
AU		Wiley, S. et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3: 673-82, 1995 (XP-000672297)

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.